Revenue

As Milestone Pharmaceuticals gears up for its Q3 2026 earnings, all eyes are on CARDAMYST's commercial uptake and the pivotal Phase 3 AFib trial expansion.

As Elanco prepares for the UBS Global Healthcare Conference, investors are watching how the animal health giant balances financial rigor with digital innovation.

A widespread cyclospora outbreak and surging freight costs battered Marzetti's Q1 margins, though its Bachan's acquisition provided a crucial revenue cushion.

LGI Homes reports strong Q3 2026 earnings with a 10.2% revenue increase, but a surge in cancellation rates and a shrinking backlog signal growing affordability pressures in the entry-level housing market.

Authentic Brands Group has finalized its acquisition of Lee from Kontoor Brands, transitioning the 137-year-old denim icon into an asset-light licensing model.

PharmaEssentia’s breakthrough ET treatment secures approvals across the US and Asia, but a bitter decade-long licensing dispute leaves Europe behind.

Armed with a massive COVID-19 cash reserve, BioNTech is aggressively reshaping its pipeline, pairing novel cancer therapies while navigating clinical hurdles.

Zebra Technologies posted a 22% sales surge in Q3 2026, driven by frontline AI and Elo Touch. But looming debt and memory costs reveal a complex road ahead.

By embedding artificial intelligence into core claims workflows and expanding into commercial health plans, CorVel has unlocked massive operational leverage.

As BeOne Medicines heads to the Jefferies Global Healthcare Conference, the tri-listed oncology giant must prove its pipeline serves both investors and humanity.

Hopscotch Groupe's aggressive entry into the EU institutional market reveals a macro-trend: the lucrative convergence of corporate PR and European democracy.

Merck KGaA is selling its CDMO business to Lonza for a mid-triple-digit million-euro sum, signaling a major shift toward high-margin life science tools.

TETRA Technologies just posted its best Q3 revenue in a decade, but the real story is its strategic pivot toward AI data centers and battery minerals.

As mega-clearing firms abandon smaller broker-dealers, AtlasClear is stepping in to provide essential infrastructure and drive institutional innovation.

Charles Anderson analyzes HealthStream's Q3 results, exploring how a $40M equity raise and cyber incident costs reveal the true price of scaling health tech.

First American's CTO Jody Mulkey was named a 2026 Tech Trendsetter. We explore how agentic AI and instant decisioning are transforming the title industry.

Ryman Hospitality's record Q3 results prove corporate conventions are defying macro fears, fueled by a $1.38B Orlando acquisition and surging banquet spending.

As Adeia lowers its 2026 guidance due to delayed licensing deals, new CEO Dipti Vachani faces the challenge of smoothing out a volatile patent revenue model.

Insight Enterprises signals a major shift toward high-margin cybersecurity services, appointing former FS-ISAC CEO Valerie Abend to lead its global practice.

As the Centre Pompidou undergoes a massive renovation, a new partnership with JCDecaux highlights the growing reliance on corporate advertising to fund heritage.